GlassScriptPhysician profile
John R Ciotti
NPI 1992186985
$23,846.32
in general payments reported to CMS, 2019-2025
15 companies · $2,129 in 2025
The $2,129 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $151 · 2021: $5,745 · 2022: $8,874 · 2023: $4,419 · 2024: $1,749 · 2025: $2,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,201 · Food and Beverage: $3,596 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,201.00 |
| Food and Beverage | $3,596.28 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,808.02 | 2019-2025 | |
| Emd Serono, INC. | $7,135.52 | 2019-2025 | Evobrutinib |
| Genentech USA, INC. | $2,074.64 | 2021-2023 | Ocrevus |
| Tg Therapeutics, INC. | $1,703.18 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $1,020.00 | 2021 | |
| Genzyme Corporation | $978.39 | 2021-2025 | |
| Celgene Corporation | $933.54 | 2021-2025 | Zeposia |
| Biogen, INC. | $718.16 | 2022-2025 | Vumerity, Tysabri |
| E.R. Squibb & Sons, L.L.C. | $563.49 | 2022-2024 | Zeposia |
| Horizon Therapeutics Plc | $289.96 | 2021-2023 | Uplizna |
| Amgen INC. | $232.46 | 2024-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $157.78 | 2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $94.11 | 2023 | Acthar |
| Abbvie INC. | $85.81 | 2025 | |
| Genentech, INC. | $51.26 | 2024-2025 | Ocrevus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ciotti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.